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Abstract

LISA GREEN. Characteristics and Function of PVT Synaptic Inputs to NAc Cell Populations
Following Opioid Use. (Under the direction of JAMES M. OTIS)

The posterior paraventricular thalamus (pPVT) plays a crucial role in reward-seeking
behaviors due to its connectivity with brain structures which are important for reward processing,
such as the nucleus accumbens shell (NAcSh). Previous studies have shown that PVT neurons
form functional synapses with dopamine 1 receptor- (D1) and dopamine 2 receptor-expressing
(D2) medium spiny neurons, as well as parvalbumin (PV) interneurons within NAc; however,
how pPVT connections to downstream NAc (pPVT-NAc) neurons contribute to reward-seeking
is unclear. While we have recently shown that pPVT-NAc can act to inhibit reward-seeking when
it is inappropriate, it is unknown how pPVT downstream targets contribute to this behavioral
inhibition. Additionally, I have shown that chronic heroin use causes pPVT-NAc to become
dysfunctional by no longer suppressing reward-seeking, yet it remains unknown how chronic
heroin use changes pPVT innervation of NAc neurons. This project uses patch-clamp
electrophysiology in combination with optogenetics to characterize the innervation of pPVT onto
downstream NAc neurons. I hypothesized that pPVT innervation of PV interneurons within the
NAc is critical for suppression of reward-seeking behavior and that this synaptic input is inhibited
by opioid use. Using D2- and PV-cre transgenic mice, I expressed channelrhodopsin in pPVT
projection neurons to the NAc, and patched onto fluorescently tagged D2-, D2+, or PV+ neurons.
In naïve animals, I evaluated the innervation of pPVT on each cell type and determined whether
calcium-permeable AMPA receptors (CP-AMPARs) were present, to identify the mechanism of
excitatory input provided by the pPVT. I found that pPVT forms functional synapses with D1s
ix

and D2s and that this innervation does not utilize CP-AMPARs under normal circumstances. The
posterior PVT also innervates PVs, and induces CP-AMPAR activation, seen through AMPAR
rectification index and CP-AMPAR antagonist (IEM-1460) sensitivity. Next, I measured
plasticity in pPVT synaptic inputs to each cell type 24 hrs following the last day of either saline
or heroin self-administration, or heroin extinction. I found that the pPVT-NAc pathway
undergoes synaptic plasticity following opioid use through a reduction of CP-AMPARs, reducing
synaptic input between pPVT and NAc. Results show that pPVT neuronal innervation of PVs
within the NAc may play a role in the suppression of reward-seeking behaviors in relation to
heroin use and heroin extinction and leads to feedforward inhibition of D1 and D2 neurons.
Together, these data reveal that pPVT differentially innervates these cell types, and the synaptic
input between pPVT and PVs is inhibited by opioid use. Furthermore, these data aid in the
identification of precise circuits that are required for the suppression of reward-seeking and reveal
how they are modified in opioid use disorder.
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Chapter 1: Introduction
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Introduction
Opioid misuse and addiction constitute a public health crisis often leading to significant
social and economic costs, physical and mental debilitation, and death. Between the years of 1999
and 2019, nearly 500,000 people died from opioid overdose, including both prescription and illicit
opioids (Centers for Disease Control and Prevention, 2021). While prescription opioids are
efficacious in their analgesic effects, dependence and misuse can be a dangerous outcome.
Although the risks and impact of opioid use is known among the medical community, opioids
continue to be prescribed, and the increased availability of prescription opioids contributes to the
rate of opioid use disorder (OUD) and overdose-related deaths (Han et al., 2017; Martins et al.,
2012). To address this issue, several organizations have suggested important changes to clinical
practice, such as modified prescribing guidelines for pharmacotherapy, behavioral therapy, safe
supplies accessible to those dependent on opioids, and broader access to medications for treating
OUD (Santi, 2022). These much-needed changes can be facilitated by a better understanding of
the pharmacological and behavioral adaptations that result from the use of opioids that underlie
their adverse outcomes, such as addiction and overdose. Opioid use has been shown to affect
reward-seeking in a manner which outlasts the presence of the drug in the brain, suggesting that
it may contribute to the reorganization of neural circuits to promote drug-seeking behavior (Nall
et al., 2021). The suppression of natural and inappropriate reward-seeking, such as when seeking
a reward presents negative or harmful impacts on oneself or others, is an important component
of drug addiction, as the inability to suppress reward-seeking behavior is a hallmark of OUD
(Koob & Le Moal, 2008). Despite this knowledge, it is unclear how critical brain circuits for the
suppression of reward seeking behaviors are modified by opioid use.
The paraventricular thalamus (PVT) is a brain region that has been shown to play a role
in natural and inappropriate reward-seeking behaviors through its connectivity with brain
2

structures important for reward processing (Giannotti et al., 2021; Keyes et al., 2020; Otis et al.,
2019). PVT neurons projecting to the nucleus accumbens (NAc) have been shown to act as an
interface for reward processing by integrating relevant inputs to accurately inform rewardseeking behavior (Xu et al., 2020). Activity of the PVT-NAc is necessary and sufficient for
reward-seeking behaviors. We and others have shown that activation of PVT-NAc discourages
reward-seeking behaviors in drug naïve mice, whereas inhibition of this pathway encourages
reward-seeking behavior when it is inappropriate (Giannotti et al., 2021; Keyes et al., 2020; Nall
et al., 2021; Otis et al., 2019; Zhu et al., 2016). Thus, PVT-NAc has been shown to act as a brake
for reward-seeking, but how downstream neurons contribute to this behavioral inhibition is
unknown. Determining the cell populations in NAc that are responsible for the increase in rewardseeking behavior upon PVT-NAc inhibition will allow for a better understanding of the
neurobiological mechanisms underlying OUD and potentially identify treatment targets for OUD.

Specific Aims and Significance
Identifying the precise circuits that are required for suppression of reward-seeking, and
understanding how those circuits are modified in OUD, could lead to development of specific
cell-type targeted therapeutics aimed to reduce relapse susceptibility. Recent work reveals that
the PVT may play a critical role in suppressing reward-seeking when such behavior would be
inappropriate. The PVT has strong connectivity with brain structures which are important for
reward processing, with dense inputs from areas that are critical for identification of external
reward-related information and internal physiological state (Choi et al., 2019; Choi and McNally,
2017; Do-Monte et al., 2017; Engelke et al., 2021; Iglesias and Flagel, 2021; Kelley et al., 2005;
Matzeu and Martin-Fardon, 2018; Millan et al., 2017; Zhou and Zhu, 2019). These inputs
converge onto single PVT projection neurons, which synaptically innervate the medial shell of
3

the NAc (Choi et al., 2019; Iglesias and Flagel, 2021; McGinty and Otis, 2020; Millan et al.,
2017). Recent data from our lab reveals that activation of this pathway abolishes reward-seeking
behaviors in drug naïve mice, whereas inhibition of this pathway can prevent the suppression of
reward-seeking behavior (Vollmer & Green et al., submitted). Thus, the PVT-NAc pathway
serves as a brake for reward-seeking, but the downstream neurons and their influence in this
behavioral inhibition are unknown. Furthermore, while recent contributions have been made to
understanding the effects of drugs of abuse on this pathway (Giannotti et al., 2021; Zhu et al.,
2016), whether PVT-NAc circuits are reorganized following opioid use remains unclear.
Previous studies reveal that PVT projections to the NAc synaptically innervate dopamine
1 receptor-expressing (D1) and dopamine 2 receptor-expressing (D2) medium spiny neurons
(MSNs) (Giannotti et al., 2021; Zhu et al., 2016). While it has been shown that the PVT also
projects to parvalbumin-expressing interneurons (PV-INs) within the NAc (Yu et al., 2017), the
contribution and function of this synaptic innervation for the suppression of reward-seeking has
not been fully evaluated. Additionally, how these synaptic inputs are modified by opioid use
remains unknown. We hypothesize that PVT neuronal innervation of PV-INs within the NAc is
critical for suppression of reward-seeking behavior, and that this synaptic contact is inhibited by
opioid use. This idea is based on preliminary data showing that pharmacological inhibition of
calcium-permeable AMPA receptors (CP-AMPARs) in the NAc shell, which are primarily
located on PV-INs, prevents PVT-NAc activation from suppressing sucrose-seeking behavior. I
will test this hypothesis in the following Aims:
Specific Aim 1: To characterize the synaptic innervation of PVT onto downstream celltype specific NAc neurons.
Specific Aim 2: To measure plasticity in PVT synaptic inputs to cell-type specific NAc
neurons following opioid use.
4
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Opioid Use and Addiction
In recent years, the number of people receiving treatment for chronic pain has increased
substantially, with estimates between 11-22% of adult U.S. citizens (Dowell et al., 2016; Nadeau
et al., 2021). Opioid use has been shown to be effective for acute and chronic pain, and shortterm use has demonstrated pain relief and efficacy (Dowell et al., 2016; Martins et al., 2012).
However, opioids have been shown to be highly addictive, often leading to medication misuse,
addiction, and overdose-related deaths (Blanco & Volkow, 2019; Lynn, 2017). Misuse of a
medication is defined as using the medication without a prescription, for an indication not
directed by the prescribing physician, or in greater amounts, more often, or longer than prescribed
(Han et al., 2017; Martins et al., 2012). According to a 2015 systematic review, 21-29% of opioidtreated patients with chronic pain misuse their prescriptions, and 8-12% become addicted (Lynn,
2017, Vowles et al., 2015). This misuse of medication can lead to substance use disorders (SUDs),
including OUD, which are indicated by compulsive substance use, tolerance with long-term use,
withdrawal during abstinence, and increased risk of premature mortality (Blanco & Volkow,
2019; Kimber et al., 2015; Lynn, 2017; Moeller & Cunningham, 2017). Opioid use disorder is a
chronic, relapsing disorder, associated with numerous physical, mental, social, and legal
impairments and distress (Bell & Strang, 2020; Blanco & Volkow, 2019).
Currently, OUD is an epidemic within the United States. Between 2015 and 2019, the
percentage of people with OUD decreased from 1.5% to 0.7%, and prescription opioid-involved
death rates decreased by nearly 7%, but total opioid- and synthetic opioid-involved death rates
increased by 6% and 15%, respectively (Centers for Disease Control and Prevention, 2021;
Substance Abuse and Mental Health Services Administration, 2020). It is estimated that there are
currently more than 2 million U.S. adults with OUD, with nearly 90,000 deaths by opioid
overdoses every year (Saini et al., 2022). While alarming, these data are not overlooked by
6

physicians and policymakers. There have been increased local, state, and federal interventions,
as well as other policy efforts, aimed at addressing the harmful effects of OUD (Bray et al., 2017;
Dart et al., 2015). These efforts encourage increased use of pharmacotherapy, behavioral therapy,
safe supplies accessible to those dependent on opioids, and broader access to medications for
treating OUD and decreasing harms associated with opioid dependence (Saini et al., 2022).
There are also numerous FDA-approved treatments to decrease the effects of withdrawal
and relapse for OUD. Methadone is a full µ-opioid receptor (MOR) agonist and is itself a schedule
II-controlled substance, meaning it has a high abuse potential and can lead to severe
psychological or physical dependence. Between 1960 and 2000, methadone became available in
opioid treatment programs, which also provide counseling and support services for patients
(Kimber et al., 2015; McCarty et al., 2018). Buprenorphine is a partial MOR agonist and is a
schedule III-controlled substance, meaning it has a lower potential for abuse but may still lead to
moderate or low physical dependence (Kimber et al., 2015; McCarty et al., 2018). As a partial
agonist, buprenorphine has a lower risk for respiratory suppression (a common adverse event
with full agonists) and is available through physicians who complete 8 hours of training and
register with the DEA; however, they are limited to a maximum of 30 patients during their first
year and 275 thereafter (Kimber et al., 2015; McCarty et al., 2018). Naltrexone is another FDAapproved treatment for opioid dependence. As a µ-OR antagonist, naltrexone prevents the
physiological effects of opioids. Naltrexone is not a controlled substance and has no potential for
addiction or dependence. Although naltrexone is effective, it has been shown to have poor
efficacy due to the need for daily dosing (Kimber et al., 2015; McCarty et al., 2018).
Interestingly, based on a review analyzing quality of life among those with OUD,
individuals who are receiving OUD treatment report lower mental health-related quality of life
compared with the general population as well as people with various medical illnesses, while
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physical well-being scores are less affected (De Maeyer et al., 2009). Although these medications
have been shown effective to increase treatment retention and decrease rates of mortality, a
comparative study showed that only 12.5% of people with OUD undergo medication-assisted
treatment (Saini et al., 2022; Wakeman et al., 2020). There are many barriers to treatment and to
decreasing OUD, such as a limited number of providers that can treat OUD, accessibility to
healthcare, and the stigma that continues to surround OUD and its treatment (Wu et al., 2016).
Like other SUDs, statistically, individuals with OUD tend to be male, unemployed, younger in
age, suffer from psychiatric disorders, have less education, and/or have a lower income, all of
which can lead to more difficulty in being able to access and afford treatment of OUD (Blanco
& Volkow, 2019).
Although there are approved methods of treatment, their long-term effectiveness and
ability to increase quality of life are not enough to diminish OUD overall. While treatment
initially helps to decrease the effects of OUD, recent reports show that OUD treatment does not
retain efficacy following long-term use, with a decrease in the rate of preventing relapse and
overdose by almost 50% following 12 months after treatment start (McCarty et al., 2018;
Wakeman et al., 2020). In addition, the social stigma perpetuated by those who believe that
recovery from OUD is a willful choice negatively impact the successfulness of treatment. It is
necessary for society to accept that OUD is a medical illness and reduce the stigma that surrounds
it, both to progress OUD treatment success and decrease the burden on those who experience it
(Olsen & Sharfstein, 2014; Saini et al., 2022).
Studies have shown that opioid use affects reward-seeking in a manner which outlasts the
presence of the drug in the brain, suggesting that it may contribute to the reorganization of neural
circuits to promote drug-seeking behavior (Kalivas & Volkow, 2005; Kallupi et al., 2020; Koob
& Volkow, 2016; Matzeu & Martin-Fardon, 2018; Nall et al., 2021; Zhou & Zhu, 2019).
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Therefore, to reduce the impact of OUD and relapse caused by the inability to suppress
maladaptive reward seeking, it is critical that the investigation of OUD causes, treatments, and
prevention continues. The suppression of reward seeking is an important component of drug
addiction, as the inability to suppress maladaptive reward-seeking behavior is a hallmark of OUD.
Despite this knowledge, it is currently unclear how brain circuits that are critical for the
suppression of reward-seeking behaviors are modified by opioid use.

Reward Circuitry
The Reward Pathway
The ability to appropriately decipher and respond to the environment plays a key role in
the lives of all living organisms and is necessary for survival (Logan, 1985). Properly assessing
risk and reward provides the opportunity to successfully hunt and scavenge for food, prioritize
activities, and increase productivity when appropriate (Mansouri et al., 2009; Stephens & Krebs,
1986). This natural reward-seeking behavior and goal-directed motivation is learned and
characterized by a change in responsiveness to a particular stimulus (Arias-Carrion & Poppel,
2017). The learned ability to approach rewards and predict and respond to environmental cues is
reliant upon the network of multiple brain structures, including the amygdala, hippocampus, and
prefrontal cortex (PFC) (Choi & McNally, 2017). Additionally, such behavioral responses have
recently been associated with the modulatory effects of dopamine on these regions and their
efferent connections (Arias-Carrion & Poppel, 2017; Wise, 2004). Although there is an
understanding of which brain structures contribute to the behavior required for interpreting the
environment and assessing risks, more investigation is needed about how these structures interact
to produce this effect and, importantly, how this natural reward-seeking becomes maladaptive
following chronic opioid use (Choi & McNally, 2017; Giannotti et al., 2021; Keyes et al., 2020).
9

The reward pathway is a collection of brain structures and neural circuits that modulate
reward-related cognition and emotion and are thought to undergo changes in cellular and synaptic
organization following drug use (Kalivas & Volkow, 2005; Koob & Volkow, 2018; Matzeu &
Martin-Fardon, 2018; Zhou & Zhu, 2019). These changes, known as neuroplasticity, are thought
to promote the maladaptive, inappropriate, and compulsive behavior highlighted in addiction and
OUD (Koob and Volkow, 2018; Matzeu & Martin-Fardon, 2018; Zhou & Zhu, 2019). In the early
stages of behavioral neuroscience research, Olds and Milner (1954) made advancements in
understanding goal-oriented motivation through positive reinforcement following electrical
stimulation of specific brain regions (Gardner, 2011). This was the first study to recognize that
specific brain regions may contribute to the behavioral effect of reward seeking and it set the
stage for decades of research contributing to brain mapping and the neurocircuitry involved in
reward-seeking, particularly that which is evolutionarily necessary for reproduction, fitness, and
survival. Although much progress has been made in this area, the ways in which these brain
regions communicate and cooperate to gate behavioral responses are not fully understood
(Engelke et al., 2021; Gardner, 2011; Iglesias & Flagel, 2021). More recent research by Kelley
et al. (2005) progressed the knowledge of this circuitry further, proposing a deeper understanding
of hypothalamic-thalamic-striatal contributions to energy balance, arousal, and food reward
(Iglesias & Flagel, 2021).
While many studies have focused on the rewarding effects of drugs of abuse, it is
important to provide a full scope of how recreational use can evolve into compulsive use,
addiction, and relapse. It is well known that dopamine serves a vital role in addiction, as it is a
way to reinforce behavior and is considered essential in the reward system (Arias-Carrion &
Poppel, 2017; Gardner, 2011; Koob et al., 1986; Volkow et al., 1997). Dopamine is known to
participate in pain, pleasure, fear, anger, and other emotional and motivational behavior, located
10

abundantly throughout the cortical and limbic regions. These regions consist of the PFC, which
regulates motivational salience and the intensity of behavioral response, the amygdala, bed
nucleus of the stria terminalis, ventral tegmental area (VTA), PVT, NAc, hippocampus, dorsal
striatum, hypothalamus, thalamus, locus coeruleus, and the zona incerta. (Koob & Volkow, 2016;
Matzeu & Martin-Fardon, 2018; Rajmohan & Mohandas, 2007). Each brain region can contribute
differently throughout the stages of addiction due to the segregation of neural systems and neuron
populations and how they respond to stimuli (Choi & McNally, 2017; Gore et al., 2015; Lammel
et al., 2012; Namburi et al., 2015).
In general, OUD can be characterized by three progressive stages: Stage 1 consists of the
acute effects of drug use, Stage 2 is the transition into addiction, and Stage 3 is preoccupation
and anticipation (Gardner, 2011; Kalivas & Volkow, 2005; Koob & Volkow, 2016). During the
first stage, individuals use drugs of abuse in a manner which allows reward-based use to transition
into chronic use. This reinforcement of behavior is encouraged through the release of dopamine
and opioid peptides in the ventral striatum, which is synonymous with the nucleus accumbens
(Koob & Volkow, 2016; Salgado & Kaplitt, 2015). During the second stage, the effects of
withdrawal become apparent, causing decreases in dopaminergic, serotonergic, and gamma
aminobutyric acid (GABA) transmission (Davidson et al., 1995; Koob & Volkow, 2016),
increases in µ-OR response, and increase in glutamatergic transmission in the NAc (Koob &
Volkow, 2016; Stinus et al., 1990). During the third stage, preoccupation and anticipation often
lead to relapse, which has been shown to be mediated by the prelimbic cortex and NAc. Dopamine
activity through D1 receptors in the PFC have also been shown as a result of stress-induced
reinstatement, as well as D1 and D2 receptor activity in the PFC as a result of drug-induced
reinstatement (Koob & Volkow, 2016; Matzeu & Martin-Fardon, 2018; Vranjkovic et al., 2018).

11

Figure 1. Reward Circuitry. Reward system network, displaying glutamatergic (green),
dopaminergic (purple), and GABAergic (red) projections. The dotted lines depict afferent
projections from the PVT and VTA. AMY, amygdala; BNST, bed nucleus of the stria terminalis;
CTX, cortex; Hipp, hippocampus; Hyp, hypothalamus; LC, locus coeruleus; NAc, nucleus
accumbens; PFC, prefrontal cortex; PVT, paraventricular thalamus; VTA, ventral tegmental area.
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Some of the changes seen following drug use and reinstatement have been linked to
activity within the amygdala, due to its increase in activity following multiple types of induced
reinstatement (Grimm & See, 2000; Matzeu & Martin-Fardon, 2018; Meil & See, 1997) and its
involvement in fear-motivated behaviors (Kalivas & Volkow, 2005), but these are now thought
to also be closely attributed to the PVT (Do-Monte et al., 2017). Specifically, investigation of the
PVT-NAc pathway has been gaining traction recently. It has been shown that activity within the
PVT-NAc pathway is necessary to mediate behavioral aversion (Zhou & Zhu, 2019), and that
silencing this pathway causes profound behavioral responses, abolishing aversive symptoms of
opiate withdrawal (Zhu et al., 2016). Furthermore, disruption of synaptic transmission from select
PVT-NAc projection neurons resulted in decreased cocaine self-administration in rats (Neumann
et al., 2016). Additional analysis of this pathway and its role in reward seeking and addiction is
critical to elucidate the neural network and plasticity that occurs due to chronic opioid use.
Paraventricular Thalamus
The PVT has recently gained the attention of behavioral neuroscientists for its potential
contribution to reward seeking and addiction. Following the initial introduction of the reward
system by Olds and Milner (1954), the PVT was implicated in motivation and learning through
experiments revealing its electrical stimulation caused rewarding and reinforcing effects, as well
as characterization of changes in its activity following exposure to drugs of abuse (Clavier &
Gerfen, 1982; Cooper & Taylor, 1967; Deutch et al., 1998; Pierce & Kalivas, 1997). Using this
foundational research, the PVT has been and continues to be the focus of many researchers
investigating drug addiction and relapse (James & Dayas, 2013; Kirouac, 2015; McGinty & Otis,
2020; Millan et al., 2017; Zhou & Zhu, 2019). The PVT is seated in the dorsal midline thalamus
and receives inputs from regions involved in arousal and motivational states, such as the zona
incerta, hypothalamus, prelimbic cortex, infralimbic cortex, ventral hippocampal subiculum,
13

locus coeruleus, and pontine reticular formation (Choi et al., 2019; Choi & McNally, 2017; DoMonte et al., 2017; Engelke et al., 2021; Iglesias & Flagel, 2021; Kelley et al., 2005; Matzeu &
Martin-Fardon, 2018; Millan et al., 2017; Zhou & Zhu, 2019). The PVT projects to the amygdala,
infralimbic cortex, PFC, bed nucleus of the stria terminalis, ventral hippocampal subiculum, and
the NAc. The location of the PVT and its afferent and efferent connections allow it to receive,
integrate, and forward important information about internal states, causing the PVT to be essential
in regulating arousal, attention, energy balance, food consumption, and motivational conflict
(Choi et al., 2019; Choi & McNally, 2017; Do-Monte et al., 2017; Engelke et al., 2021; Iglesias
& Flagel, 2021; James & Dayas, 2013; Kelley et al., 2005; Matzeu & Martin-Fardon, 2018;
McGinty & Otis, 2020; Millan et al., 2017; Zhou & Zhu, 2019).
An important characteristic of the PVT is the diversity and heterogeneity of the PVT itself.
It has been shown that the PVT can be divided into two sections based on anatomical boundaries
which define cellular function and projections leading to distinct traits: anterior PVT (aPVT) and
posterior PVT (pPVT) (Choi et al., 2019; Gao et al., 2020; Iglesias & Flagel, 2021; McGinty &
Otis, 2020; Millan et al., 2017). The aPVT receives projections from the ventral hippocampal
subiculum, hypothalamus, and infralimbic cortex while projecting to the dorsomedial NAc shell.
Alternatively, the pPVT receives projections from the hypothalamus, prelimbic cortex, and
infralimbic cortex, and projects to the ventromedial NAc shell, amygdala, and bed nucleus of the
stria terminalis (Choi et al., 2019; Iglesias & Flagel, 2021; McGinty & Otis, 2020; Millan et al.,
2017). Based on the distinct connectivity, it has been shown that aPVT is implicated in mediating
the effects of reward omission due to its projections from the hypothalamus, while pPVT plays a
role in approach and avoidance conflict motivation (Choi & McNally, 2017; Do-Monte et al.,
2017; Engelke et al., 2021; Giannotti et al., 2018; Iglesias & Flagel, 2021; McGinty & Otis,
2020). Importantly, the division between aPVT and pPVT can be ambiguous and conflicting, as
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the anatomical, cellular, and functional characteristics which are used to classify aPVT and pPVT
occur along a gradient (McGinty & Otis, 2020; Iglesias & Flagel, 2021). Due to the lack of clarity,
recognition, and individual investigation regarding these two distinct PVT portions and the result
of having separate neural projections, previous literature has reported conflicting information
regarding the role that the PVT plays in reward-seeking behavior (Do-Monte et al., 2017;
McGinty & Otis, 2020). This poses challenges in the literature when defining these PVT portions
and their implications and calls for a uniform understanding to provide clear research in the
future.
Another potential cause of the heterogeneity within the PVT is the complexity of the
neurotransmitters involved, such as dopamine, GABA, endogenous opioids, cocaine-andamphetamine-regulated transcript (CART), and orexin (Iglesias & Flagel, 2021; Kirouac, 2015;
McGinty & Otis, 2020). The PVT is composed of excitatory projections using glutamate and
aspartate, and while the PVT does not contain inhibitory GABAergic interneurons (INs), it does
receive innervation from multiple regions, including the zona incerta, hypothalamus, and pontine
reticular formation (Arias-Carrion & Poppel, 2017; Iglesias & Flagel, 2021; Kirouac, 2015;
McGinty & Otis, 2020; Zhou & Zhu, 2019). Of the glutamatergic projections from the PVT, one
of particular interest is the connections between the PVT and the NAc. Recent studies have stated
that the PVT-NAc pathway is highly implicated in reward-seeking behavior which could be
promoted by the PVT-mediated release of dopamine in the NAc by excitatory afferents (Iglesias
& Flagel, 2021; Kirouac, 2015). As some studies have suggested, this effect is likely mediated
by postsynaptic mechanisms (Beas et al., 2018; Kirouac, 2015), expanding our view to the
downstream events of the PVT. Analyzing the PVT-NAc pathway could provide valuable
information about the pathology and processes of drug addiction.
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Nucleus Accumbens
The NAc is a region known for regulating emotion and reward-related behavior by
interpreting information provided by other regions (Xu et al., 2020). The limbic and motor
systems both offer projections to the NAc, particularly the PFC, PVT, hippocampus, and VTA.
As previously discussed, the PVT provides glutamatergic inputs to the NAc, which are thought
to influence the motivation of behaviors and rewards (Carlezon & Thomas, 2009; Castro &
Bruchas, 2019; Engelke et al., 2021; Iglesias & Flagel, 2021; James & Dayas, 2013; Kirouac,
2015). Similar to the PVT, the NAc can be separated into two subcompartments: the NAc core
(NAcC) and the NAc shell (NAcSh). These distinct regions of the NAc are dictated by anatomical
location and cellular distribution. The NAcC is found surrounding the anterior commissure,
receiving dopaminergic inputs from the VTA and glutamatergic inputs from the PFC, and
innervates the VTA and ventral pallidum (VP) (Kupchik et al., 2015; Nestler, 2005). Due to this
circuitry, the NAcC is necessary for mediating learned behaviors. The NAcC is encapsulated by
the NAcSh, which can be further dissected into lateral and medial NAcSh. The medial NAcSh
receives direct inputs from the lateral hypothalamus and is also reciprocally connected to the
VTA and VP. Based on recent data, the NAcSh is important for regulating motivational salience,
consumption, and learning motivation in connection to stimuli (Castro & Bruchas, 2019; Kalivas
& Volkow, 2005; Kelley et al., 2005; Kirouac, 2015; Xu et al., 2020). While both the NAcC and
NAcSh have diversity in cellular populations and projections, it has been shown that both regions
are innervated by different areas of the PVT (Kirouac, 2015). PVT and NAc have been identified
as structures important in the neural circuitry controlling reward states and drug addiction, though
the relationship between them and how this pathway contributes has only recently been under
investigation. Activation of the PVT-NAc pathway has been shown to drive aversion and mediate
withdrawal (Giannotti et al., 2021; Keyes et al., 2020; Pribiag & Lim, 2020; Zhu et al., 2016). In
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a recent study, through optogenetic and chemogenetic methods, activity within the PVT-NAc
pathway was sufficient and necessary for continued heroin-seeking following abstinence but the
same effects were not seen after extinction (Giannotti et al., 2021). This is consistent with another
study implicating the PVT-NAc pathway in the aversive effects of opioid withdrawal (Zhu et al.,
2016), indicating that opioid exposure causes synaptic plasticity leading the activity of this
pathway to contribute to, rather than avoid, reward-seeking. These results were shown to cause
synaptic plasticity within the subpopulation of D1-expressing MSNs (D1-MSNs) within the NAc
following heroin extinction (Giannotti et al., 2021). Another study suggests that following shortterm withdrawal from morphine, PVT input to D2-expressing MSNs (D2-MSNs) increases and
causes inhibition of D1-MSNs which project to the lateral hypothalamus, leading to morphineassociated memory retrieval and relapse (Keyes et al., 2020).
The effects of the opioid and neuropeptide systems within the NAc may overlap and
contribute to the behavioral impacts of addiction, but the exact role of these systems and how
they interplay is not well known (Castro & Bruchas, 2020). Although the exact mechanism of the
PVT-NAc pathway and its role in addiction and relapse are not yet understood, it is clear there is
a dopaminergic role following opioid exposure within the NAc (Castro & Bruchas, 2020).
Dopamine is essential in controlling reward in response to many drugs of abuse, and dopamine
dysfunction within the NAc is thought to be a contributing factor in the rewarding and
motivational factors of addiction (Arias-Carrion & Poppel, 2017; Kirouac, 2015; Nestler, 2005;
Xu et al., 2020). Drugs of abuse have been shown to cause elevated extracellular dopamine levels
within the NAc, and that reduced activity of MSNs within the NAc produces rewarding effects,
whereas elevated activity of MSNs within the NAc causes aversive behaviors (Carlezon &
Thomas, 2009; Zhou & Zhu, 2019; Zhu et al., 2016). Another unique characteristic of the NAcSh
is the high amount of CART peptides within D1-MSNs, although how this contributes to the
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mechanism of reward-seeking remains unknown (Hubert et al., 2010; Castro & Bruchas, 2019).
Overall, with MSNs being the majority neuronal population within the NAc (Carlezon & Thomas,
2009; Castro & Bruchas, 2019; Giannotti et al., 2021; Xu et al., 2020), a closer look at their
activity and characteristics following opioid use, and the relationship between MSNs and other
cellular populations within this system, could provide valuable insight into how the PVT-NAc
pathway contributes to addiction and relapse.

Cell-Type Specificity
Medium Spiny Neurons
It is well known that dopamine has the ability to control motivational impulses, rewardseeking behaviors and cognition, and that the activity of dopamine neurons is a result of rewardanticipation (Arias-Carrion & Poppel, 2007). It has been shown that many drugs of abuse cause
increased extracellular concentrations of dopamine in the NAc, and that dopaminergic regulation
of motivation in response to conditioned stimuli can be localized in the NAc. A large supplier of
dopamine to the NAc comes from the VTA, and this pathway is a part of the mesolimbic
dopamine system (Arias-Carrion & Poppel, 2007; Carlezon & Thomas, 2009; Ferre et al., 2010;
Meredith et al., 1992; Merrer et al., 2009; Olsen, 2011; Robison et al., 2011; Simmons & Self,
2009; Xu et al., 2020). The mechanisms of dopamine binding include dopamine release from the
synaptic cleft and subsequent diffusion in the extracellular fluid where it undergoes metabolism
and reuptake via dopamine transporters. Synaptic plasticity regarding these mechanisms of
dopamine release and binding are thought to be responsible for reward learning and memory
formation (Arias-Carrion & Poppel, 2007; Robison et al., 2011).
MSNs are named based on their medium-sized somas, which are roughly 14µm in
diameter (Castro & Bruchas, 2019; Meredith et al., 2008; Wilson et al., 1983). These cell types
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are GABAergic neurons with extremely low baseline firing rates despite having a high density of
dendritic spines, and are known to have leaky potassium channels, which lead to further
hyperpolarization (Castro & Bruchas, 2019; Gittis et al., 2011). MSNs are 90-95% of the total
neuron population within the NAc, with the remaining 5-10% being cholinergic and GABAergic
interneurons (Carlezon & Thomas, 2009; Castro & Bruchas, 2019; Ferre et al., 2010; Gittis et al.,
2011; Robison et al., 2011; Xu et al., 2020; Yager et al., 2015). While having many similarities,
MSNs can be dissected into two groups based on neurochemical distinctions: D1-receptor
expressing MSNs (D1-MSNs) and D2-receptor expressing MSNs (D2-MSNs) (Arias-Carrion &
Poppel, 2007; Castro & Bruchas, 2019; Robison et al., 2011; Xu et al., 2020; Yager et al., 2015).
The majority of MSNs only express one type of dopamine receptor, but it has been reported that
anywhere between 5-30% of MSNs within the NAc can express both D1 and D2 receptors (AlHasani et al., 2015; Castro & Bruchas, 2019; Kupchik et al., 2015; Yager et al., 2015).
These D1- and D2-MSNs make up the direct and indirect pathways (Carlezon & Thomas,
2009; Xu et al., 2020). The direct pathway neurons express D1-like receptors, which include
subtypes D1A-1D and D5), as well as adenosine A1 receptors, AMPA and NMDA receptors,
cholinergic (M1 and M4) receptors, endogenous opioid peptide dynorphin, and substance P. The
D1 receptors on the MSNs within the direct pathway are coupled to stimulatory G-proteins which
activate adenylate cyclase and leads to excitation of these GABAergic MSNs, which then project
to the midbrain (particularly the VTA, VP, and substantia nigra) (Arias-Carrion & Poppel, 2007;
Carlezon & Thomas, 2009; Castro & Bruchas, 2019; Ferre et al., 2010; Kupchik et al., 2015;
Nishi et al., 2011; Xu et al., 2020; Yager et al., 2015). Using transgenic mice to analyze synaptic
plasticity following heroin self-administration and extinction or abstinence, D1-MSNs have been
shown to undergo long term depression in mice following abstinence but not extinction, while
D2-MSNs underwent long term depression after both abstinence and extinction (Giannotti et al.,
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2021). Based on this result, it was seen that synaptic plasticity occurred uniquely in D1-MSNs
following extinction and that this decreases the ability of the PVT-NAc pathway to drive aversion
and heroin relapse. In addition, protein FosB, which is thought to be involved in motivation and
addiction, is induced in D1-MSNs following chronic exposure to drugs of abuse (Robison et al.,
2011). In comparison, the indirect pathway neurons express D2-like receptors, which include D2,
D3, and D4 subtypes, as well as adenosine A2 receptors, AMPA and NMDA receptors,
cholinergic (M1 and M4) receptors, CB1 receptors, and the endogenous opioid peptide
enkephalin. The D2 receptors are coupled to inhibitory G-proteins and inhibit adenylate cyclase
while activating potassium channels, leading to inhibition of the GABAergic MSNs which project
to the VP and subthalamic nucleus (Arias-Carrion & Poppel, 2007; Carlezon & Thomas, 2009;
Castro & Bruchas, 2019; Ferre et al., 2010; Nishi et al., 2011; Xu et al., 2020; Yager et al., 2015).
Previous studies have seen that the adenosine A2 receptors in D2-MSNs are responsible for the
release of GABA, and that this function is critical in reward-seeking behavior (Carlezon &
Thomas, 2009; Ferre et al., 2010). Recently, D2 receptor expression has been shown to be
important and necessary for the rewarding effects of drugs of abuse, and D2 receptor function in
the NAc is required for dopamine to inhibit the indirect pathway (Carlezon & Thomas, 2009).
Multiple studies support this idea, as mice lacking D2 receptors have reduced sensitivity to
cocaine-produced reward (Welter et al., 2007), and ablation of D2 receptors causes similar effects
to morphine (Maldanado et al., 1997). Additionally, it is shown that the excitatory transmission
between the PVT and D2-MSNs increases following chronic morphine exposure, due to synaptic
plasticity on D2-MSN synapses, and that this change is necessary for aversive states during opioid
withdrawal (Zhu et al., 2016). Interestingly, MSNs can also synapse onto nearby MSNs within
the same pathway, but it is important to note that MSNs within the indirect pathway can also
synapse onto MSNs within the direct pathway, leading to an imbalance in local MSN inhibition
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within the NAc (Castro & Bruchas, 2019). There is conflicting evidence for the necessity of
dopamine activity in reward behaviors with focus shifting to the effects of reduced activity in
NAc MSNs. Many studies investigate this, with data showing that D2 receptor blockade
attenuates dopamine-dependent reward, but that blockade of glutamatergic NMDA receptors in
the NAc is also sufficient for reward, leading to the idea that reducing NAc MSN excitability can
be dopamine independent (Carlezon & Thomas, 2009; Carlezon & Wise, 1996; Olds, 1982).
MSNs also express glutamate receptors such as AMPA and NMDA receptors (Carlezon
& Thomas, 2009). The interactions of dopamine and glutamate with MSNs can be complex as
glutamate contacts the heads of dendritic spines while dopamine inputs locate to the spine neck
(Freund & Smith, 1984; Yager et al., 2015; Xu et al., 1989). The interactions between inputs can
compete for control of these MSNs since glutamate and D1 receptors are excitatory while D2
receptors are inhibitory (Carlezon & Thomas, 2009; Yager et al., 2015). In addition, activation
of D1 receptors can cause the phosphorylation of AMPA and NMDA receptors on MSNs, leading
to changes in subunit composition and receptor expression, causing the interactions between these
receptors to be multifaceted (Carlezon & Thomas, 2009). While dopamine activity has been
linked to compulsive drug use, glutamate activity is another important factor that has been linked
to relapse following drug extinction. The NAc receives glutamatergic inputs from the VTA,
hippocampus, PFC, amygdala, and the PVT. Following chronic drug use, the glutamate system
can become dysregulated and lead to increased glutamate release from the PFC to the NAc during
drug relapse, and changes in AMPAr expression and spine morphology in NAc MSNs are seen
following behavioral sensitization of drugs of abuse. While this leads to glutamate release and
synaptic plasticity, the glutamatergic changes following behavioral sensitization are not always
consistent (Quintero, 2013; Scofield et al., 2016). Overall, recent work supports the general
understanding that a reduction in activity of NAc MSNs supports reward, while an increase in
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NAc MSN activity leads to aversion, but the precise mechanisms of this behavioral affect and
inspection of pathway circuitry and behavioral contributions requires further investigation.
Adding to the complexity of cellular and regional classifications within the NAc, there is
another distinction that can be categorized in two manners: the matrix and the patch. The matrix
tissue is calbindin-rich and makes up 85-90% of the NAc. Found throughout the matrix, the areas
of patch tissue, also known as striosomes, have a low amount of calbindin and
acetylcholinesterase but has a high amount of µ-ORs (Castro & Bruchas, 2019). These µ-ORs are
expressed on NAc MSNs, and the patch tissue contains both direct and indirect MSNs (Figure
6F) (Carlezon & Thomas, 2009; Castro & Bruchas, 2019; Mansour et al., 1995). As it is known
that MSNs can synapse onto other MSNs with certain restrictions, it is also observed that D2MSNs in patch tissue can synapse onto D1-MSNs in patch tissue, but not those within matrix
tissue (Castro & Bruchas, 2019). The presence of µ-ORs on MSNs allows the potential for the
activity of µ-ORs to cause behavioral effects that occur independently or downstream of those
caused by dopamine activity (Carlezon & Thomas, 2009), adding another layer of intricacy of
the circuitry within the NAc.
µ-Opioid Receptors
Most opioid drugs, including morphine, heroin, fentanyl, codeine, oxycodone, tramadol,
and others, activate opioid receptors, clinically leading to the analgesic properties intended;
however, the rewarding and euphoric effects can lead to the chronic use and abuse seen in drug
addiction (Castro & Bruchas, 2019; Cuitavi et al., 2021; Merrer et al., 2009; Ugar et al., 2018).
Multiple works have described that opioid receptor activity is not required to produce baseline
behaviors but, when activated, can contribute to enhancing behavioral responses (Castro &
Bruchas, 2019; Cuitavi et al., 2021; Merrer et al., 2009; Ugar et al., 2018). These opioid receptors
and peptides are prominent in brain regions throughout the reward network, and with the ability
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to affect the evaluation of natural rewards, they have the vital opportunity to facilitate the reward
circuit and provide a molecular mechanism for drug addiction (Merrer et al., 2009). The opioid
system includes four GPCRs: µ (mu), δ (delta), and κ (kappa) opioid receptors, and the nonopioid
nociception receptor (Castro & Bruchas, 2019; Cuitavi et al., 2021; Simmons & Self, 2009; Xu
et al., 2020). These receptors are each encoded by a specific gene family and have the potential
to bind to a particular endogenous opioid ligand. The µ-OR is encoded by the Oprm1 gene, which
is conserved across species, and has shown to be associated with opioid dependence, alcohol
dependence, and weakened responses to opioids when this promoter becomes hypermethylated
(Cuitavi et al., 2021; Merrer et al., 2009). The µ-ORs bind to β-endorphins, produced by
proopiomelanocortin, and endomorphins. The δ-opioid receptors are encoded by the Oprd1 gene,
and bind to enkephalins, which are produced by preproenkephalin. The κ-opioid receptors are
encoded by the Oprk1 gene, and bind to dynorphins, which are produced by preprodynorphins.
Lastly, nociceptin receptors are encoded by the Opr11 gene and bind to nociceptin and orphanin
FQ peptide (Castro & Bruchas, 2019; Cuitavi et al., 2021; Merrer et al., 2009; Simmons & Self,
2009; Xu et al., 2020). Each of these opioid receptors inhibit calcium channels, activate inwardly
rectifying potassium channels, and suppress cAMP (Castro & Bruchas, 2019), and while they are
all associated with motivated behaviors, µ-ORs are responsible for the majority of analgesic and
euphoric effects of opioids and appetitive motivation (Castro & Bruchas, 2019; Cuitavi et al.,
2021; Djurendic-Brenesel & Pilija, 2016).
The µ-ORs are found throughout the reward pathway, but their mechanism for reinforcing
reward-seeking and opioid use has been debated. The relationship between the VTA and the NAc
regarding µ-OR mediation contributes to opioid and nonopioid reinforcement, which has been
confirmed through studies using local injections of µ-OR agonists and antagonists. In the VTA,
µ-ORs inhibit GABAergic neurons that project to the NAc, leading to an increase in dopamine
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release in the NAc upon activation of µ-ORs in the VTA (Cuitavi et al., 2021; Merrer et al., 2009).
The µ-ORs and their opioid peptides are also widely found throughout the striatum, in patch
tissue and on D1- and D2-MSNs within the NAc (Caref & Nicola, 2018). The NAc medial shell
has a particularly high amount of patch tissue and µ-OR expression compared to the NAc core,
which consists primarily of matrix tissue. This specificity of µ-ORs throughout the NAc medial
shell has been associated with the modulation of motivated and drug-seeking behaviors (Castro
& Bruchas, 2019). Inactivation of µ-ORs in the NAc shell simulates the aversive effects of
withdrawal, based on experiments performed using µ-OR antagonists. Using a µ-OR antagonist
in morphine-dependent rats decreased heroin self-administration where nondependent rats
showed no effects (Walker et al., 2000). Additionally, using a µ-OR antagonist, D1 or D2 receptor
antagonist all decreased self-administration of a combination drug of cocaine and heroin, whereas
using a δ-opioid receptor antagonist showed no change (Cornish et al., 2005), suggesting that µOR and dopamine receptor activation within the NAc shell are important for behavioral
reinforcement (Merrer et al., 2009). Furthermore, infusions of the µ-OR agonist DAMGO caused
reinstatement of cocaine self-administration, which was subsequently blocked by pretreatment of
the µ-OR antagonist CTAP (Simmons & Self, 2009).
Altogether, the impact of µ-ORs throughout the reward system, and especially within the
NAc shell, significantly modifies the circuitry leading to drug-associated motivation and
reinstatement. However, there is considerable integration and complexity of µ-ORs within the
reward circuitry which impairs our ability to recognize the precise roles these receptors play in
drug seeking behaviors. Further investigation of how µ-ORs interact and effect receptor
expression and cellular activity within the NAc shell is critical in better understanding their
contributions to drug addiction and relapse.

24

Interneurons
Another valuable cell type within the reward system are interneurons, which make up 510% of the remining neurons in the NAc. There are multiple populations of interneurons which
can be distinguished between morphology, molecular markers and neuropeptide expression,
calcium binding properties, and functionality (Hu et al., 2014; Nuhar et al., 2021; Ruden et al.,
2020). Within the NAc, there are three main interneurons: somatostatin, cholinergic, and
parvalbumin interneurons. Somatostatin interneurons (SOM-INs) are persistent and low
threshold spiking neurons, which release the peptide somatostatin, the enzyme neuronal nitric
oxide synthase, and GABA. SOM-INs are known to synapse onto distal portions of MSN
dendrites and are able to reach MSNs outside of the typical range of most other interneurons.
This feature is a potential cause for the limited knowledge to date of SOM-INs within the NAc
shell, as there are very few incidents of direct recordings of SOM-INs in the NAc medial shell,
causing this cell type to be very understudied (Castro & Bruchas, 2019; Gittis et al., 2011; Nuhar
et al., 2021). Cholinergic interneurons (CINs) are tonically active and release acetylcholine.
These neurons are dispersed in few numbers but are thought to influence afferent dopamine
signals in the NAc and act on muscarinic and nicotinic receptors that are expressed on NAc
MSNs. CINs express δ-opioid receptors which allow them to indirectly influence activity of
MSNs and surrounding neurons within the NAc shell by reducing the GABAergic inhibition from
D2-MSNs onto D1-MSNs. Unfortunately, this cell type is also currently understudied, and the
exact relationship and affect its activity has within the NAc is not well understood (Castro &
Bruchas, 2019; Gittis et al., 2011; Nuhar et al., 2021). Parvalbumin interneurons (PV-INs) are
fast-spiking, GABAergic interneurons that contain the calcium-binding protein parvalbumin
(PV). These neurons are not active at baseline but produce trains of action potentials over 400Hz
when stimulated, contributing to their title as fast spiking. This physiological behavior is obtained
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through the recruitment of voltage-gated potassium channels which allow for quick repolarization
and hyperpolarization (Castro & Bruchas, 2019; Ferguson & Gao, 2018; Gittis et al., 2011; Hu et
al., 2014; Klausberger et al., 2005; Nuhar et al., 2021; Ruden et al., 2020; Yamada et al., 2016).
Another factor in PV-INs fast-spiking characteristic is through the properties of PV. The protein
PV acquires presynaptic calcium which reduces the activity of calcium-activated potassium
channels which contribute to hyperpolarization. This action allows PV-INs to repolarize faster
than other interneurons, and also causes synaptic plasticity to occur (Ruden et al., 2020).
Morphologically, PV-INs have small somas and are aspiny and are able to synapse onto roughly
300 MSNs, with nearly 16 PV-INs converging onto a single MSN (Figure 6C). The ability of PVINs to interact with both direct and indirect pathway MSNs equally, and to such an extent, allows
the dramatic hyperpolarization of MSNs within a PV-INs arborized space (Castro & Bruchas,
2019; Gittis et al., 2011; Nuhar et al., 2021).
Recent studies have shown that inhibiting PV-INs cause increased activity of MSNs, and
such work supports the understanding of feedback and feedforward inhibition that PV-INs
contribute to, with the ability to convert excitatory signals into inhibitory signals within a
millisecond (Castro & Bruchas, 2019; Hu et al., 2014; Nuhar et al., 2021; Owen et al., 2018).
Other work shows that inhibiting PV-INs within the NAc activates MSNs, but also increases
calcium signaling and extracellular dopamine release in the NAc, which results in non-specific
synaptic plasticity throughout MSNs in the region (Nuhar et al., 2021; Owen et al., 2018). PVINs express and are activated by glutamatergic AMPA and NMDA receptors. Interestingly, PVINs express AMPArs which lack the GluA2 subunit, making them permeable to calcium, a
characteristic that is not normally offered by MSNs (Figure 6D) (Gittis et al., 2011; Nuhar et al.,
2021). PV-INs within the NAc mediate signals from brain regions associated with rewardseeking, including the thalamus and the PFC, and have been associated with reward-conditioned
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behavior and learning (Nuhar et al., 2021). Recently, it has been suggested that PV-INs may
contain subpopulations within the NAc, based on anatomical location and projection
characteristics, but the specific differences or physiological effects have not been determined,
causing any impact this may have on current and future research to be unknown (Castro &
Bruchas, 2019). While PV-INs and their activity within the NAc are becoming a point of interest,
it is clear that the relationship between PV-INs and MSNs within the NAc is complex and remains
a particularly critical area of study.
Calcium-Permeable AMPA Receptors
As previously discussed, glutamate is a vital excitatory neurotransmitter in the brain and
has been shown to be intricately involved in motivation and reward, depression, and addiction.
Glutamatergic AMPA and NMDA receptors contribute to the mediation of behavior and learning
by mediating synaptic plasticity throughout the reward system, and particularly within the NAc
(Goffer et al., 2013; Xu et al., 2020). These glutamate receptors affect intracellular calcium
signaling and regulation, controlling depolarization, signal transduction, and neurotransmitter
release (Carlezon & Thomas, 2009). The AMPArs contain receptor subunits GluA1, GluA2,
GluA3, and GluA4, and the change of GluA subunit expression is a potential effect of drugs of
abuse (Carlezon & Thomas, 2009; Goffer et al., 2013; Lalanne et al., 2018; Park et al., 2018). A
study investigating GluA subunit expression in AMPArs within the NAc showed an increase in
GluA1 subunit expression following cocaine exposure (Churchill et al., 1999), which increases
the influx of calcium as GluA1 subunits are permeable to calcium (Carlezon & Thomas, 2009).
Another study showed an increase in GluA2 expression in mice that overexpress FosB, linked to
being more sensitive to drug use (Kelz et al., 1999). An important characteristic of GluA2
subunits is their impermeability of calcium due to a motif within the receptor; therefore, AMPArs
containing higher amounts of GluA2 subunits are not permeable to calcium influx and are known
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as calcium-impermeable AMPArs, while those lacking the GluA2 subunits are known as calciumpermeable AMPArs (CP-AMPArs) (Carlezon & Thomas, 2009).
While the combination of expressed subunits within AMPArs is diverse, the majority of
AMPArs within the brain contain GluA2 subunits, controlling calcium ion selectivity (Lalanne
et al., 2018). Additionally, CP-AMPArs display inward rectification due to voltage dependent
channel block by polyamines, limiting current at depolarized voltages. This feature allows for
identification of CP-AMPArs while also regulating synaptic plasticity and influencing behavior
(Carlezon & Thomas, 2009; Goffer et al., 2013; Lalanne et al., 2018). Importantly, PV-INs within
the NAc express CP-AMPArs which contribute to the strong excitatory drive of these neurons
and are required for long-term potentiation of PV-INs, supported by the activity of PV-INs being
reduced when CP-AMPArs are blocked (Gittis et al., 2011; Lalanne et al., 2018; Nuhar et al.,
2021; Ruden et al., 2020). In GluA1 knockout mice, CP-AMPArs were shown to be necessary in
stabilizing behavioral motivation, as a decreased level of GluA2-containing AMPArs within PVINs contribute to the inability to control behavior and mood (Goffer et al., 2013; Zhu et al., 2016).
Based on recent research, the role that calcium plays within the NAc in regard to motivation and
reward seeking, as well as how the facilitation of calcium flux via AMPArs manipulates neuronal
depolarization and gene regulation is an emerging focus. Further investigation of CP-AMPArs
within the NAc and their influence on motivation can benefit our understanding of physiological
and molecular changes that occur following drug use and its implications on behavior and
addiction.

28

Chapter 3: Methodology

29

Introduction
To evaluate the circuitry which contributes to the behavior observed upon PVT activation,
I aimed to characterize the synaptic innervation of the PVT onto downstream cell-type specific
NAc neurons, as well as observe the presence and relevance of CP-AMPArs. This was performed
through a variety of techniques, including intracranial and intravenous surgeries, behavioral selfadministration, and patch-clamp electrophysiology. These techniques, when combined, allow for
a complex look into plasticity in PVT synaptic inputs to cell-type specific NAc neurons following
chronic opioid use.

Subjects
There have been observed sex differences in OUD indicating that men and women have
different vulnerabilities to several SUDs (Kokane & Perrotti, 2020; Sharp et al., 2022), potentially
due to ovarian hormones and their effects on dopamine transmission (Arias-Carrion & Poppel,
2017; Choi & McNally, 2017). Accordingly, both male and female mice were used to account
for any sex differences as a biological variable. To guarantee rigor and reproducibility, power
analyses were performed to ensure that experimental designs were sufficiently powered and that
concrete conclusions could be made based on the data collected. For this project, adult male and
female PV-Cre (B6.Cg-Pvalbtm1.1(cre)Aibs/J, Strain #012358) and D2-Cre (Drd2, line ER44,
RRID:MMRRC_017263-UCD) mice were used for all experiments. Mice were group-housed
pre-operatively and single-housed post-operatively, under a reverse 12:12-hour light cycle (lights
off at 8:00am) with experiments performed in the dark phase. Mice were given access to standard
chow and water at will throughout all experiments. Mice were each at least 8 weeks of age and
20g for inclusion in the study. All experiments were approved by the Institutional Animal Care

30

and Use Committee (IACUC) at the Medical University of South Carolina in accordance with
the NIH-adopted Guide for the Care and Use of Laboratory Animals.

Surgeries
For intracranial surgeries, mice were anesthetized with isoflurane (0.8-1.5% in oxygen;
1L/minute) and placed within a stereotactic frame (Kopf Instruments). Prior to and during
surgery, mice were given topical anesthetic (2% Lidocaine, Akorn), analgesic (Ketorlac, 2mg/kg,
ip), ophthalmic ointment (Akorn), and subcutaneous sterile saline (0.9% NaCl in water) for health
and pain management. Mice were given microinjections of a cre-inducible virus encoding yellow
fluorescent protein (AAV5-ef1a-DIO-eYFP) bilaterally into the NAc (relative to bregma: A/P
+1.45mm; M/L +0.65mm; D/V -4.65mm), as well as a virus encoding a red-shifted excitatory
opsin (AAV5-hSyn-ChrimsonR-tdTomato) unilaterally into the middle-posterior region of the
PVT (relative to bregma: A/P -1.55mm; M/L -1.13mm; D/V -3.30mm, -3.35mm (half injection);
20-degree angle). Following intracranial injections, a custom-made ring (stainless steel; 5 mm
ID, 11 mm OD) was adhered to the skull using dental cement and skull screws. Head rings were
scored on the base using a drill for improved adherence. Following surgery, an antibiotic
(Cefazolin, 200 mg/kg, sc) was given to reduce the possibility of infection, and mice were allowed
to recover for at least a week prior to undergoing intravenous catheter surgery.
Mice were given at least 7 days following intracranial surgery prior to undergoing
catheterization. Mice were then anesthetized as above and implanted with indwelling intravenous
catheters for drug self-administration. Catheters (Access Technologies #071709H) contained 4.5
cm of polyurethane tubing (0.012” ID/0.025” OD, rounded tip) between the subpedestal/indwelling end of the back-mounted catheter port (Plastics One #8I313000BM01) and
silicone vessel suture retention bead, with 1.0 cm extending intravenously via the right external
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jugular vein toward the right atrium of the heart. Surrounding the tubing attached to the pedestal
was larger tubing (1.5cm of 0.025” ID; 0.047” OD), and components were adhered by ultraviolet
curation. Subcutaneous catheter implantation occurred using a dorsal approach with back mounts
externalized through <5 mm midsagittal incisions posterior to the scapulae and tubing running
from the sub-pedestal base under the right clavicle into the <1 mm incision in the right external
jugular vein. I used silk sutures to adhere the catheter tubing retention bead to the external jugular
and nonabsorbable monofilament sutures to close skin incisions following confirmation of
negative pressure-induced blood backflow. Mice were given topical anesthetic, analgesic,
ophthalmic ointment, and antibiotics as above, and were given at least 7 days prior to behavioral
experiments. Patency of the catheters was maintained through daily flushing with heparinized
saline (60 units/mL, 0.02 mL), and all animals remained patent throughout behavioral
experimentation.

Self-Administration
Following at least 7 days of recovery after catheterization, mice began behavior. Selfadministration was performed in custom designed chambers which were equipped with acoustic
foam interior lining (2.5” x 24” x 18” UL 94, Professional Acoustics; 12” x 12” x 1.5” egg crate
acoustic foam tiles, OBCO) for sound proofing, Arduino-controlled infusion pumps (Med
Associates #PHM-100VS-2) and a 3 mL syringe connected to tubing (Tygon, 0.02” ID; 0.06”
OD) for intravenous drug delivery via catheter ports, a partial body restraint tube (Fisher; 01-81255) to avoid self-injury, a laptop (Lenovo Ideapad 330S; 81F5006GUS) interfaced with Arduino
software (Arduino 1.8. 12) and MATLAB software (MathWorks) to record behavioral events and
control equipment, a custom-made head-fixation station to prevent head movement, two operant
levers (Honeywell; 311SM703-T) which were wired for active/inactive responses and extended
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outward by 5cm for forelimb reach, an Arduino-controlled piezo buzzer (Adafruit; #1739) for
auditory cue, and an Arduino board (Arduino Uno Rev 3; A000066) with two electronic
breadboards (Debaser Electronics; DE400BB1-1) for self-administration equipment control.
When beginning behavior, mice first underwent 2 days of habituation, during which they
were head-restrained for 30 mins in the operant chambers. Operant levers were placed in front of
the mice during acquisition. When the active lever was pressed, cue was immediately presented
(8 kHz, 2 s), followed by a gap in time (trace interval, 1 s), and intravenous saline or drug infusion
(2 s; 12.5 µl) via tubing connected to the intravenous catheter and the syringe pump. Reinforced
active lever presses resulted in a timeout period which did not provide cue or reward, and inactive
lever presses did not provide cue or reward delivery. Mice receiving saline underwent 14 days of
2 hr saline (12.5 µl infusions; 40 infusion maximum) self-administration sessions on a fixed ratio
1 (FR1) schedule of reinforcement. Mice receiving heroin underwent 14 days of heroin selfadministration on a FR1 schedule of reinforcement using a decreasing dose design (Day 1-2: 0.1
mg/kg/12.5 µl heroin, 10 infusions maximum; Day 3-4: 0.05 mg/kg/12.5 µl heroin, 20 infusions
maximum; Day 5-14: 0.025 mg/kg/12.5 µl heroin, 40 infusions maximum), for a maximum of 1
mg/kg of heroin per session. Mice that receive heroin and undergo heroin extinction followed the
same heroin self-administration protocol followed by extinction training for 10 days, where active
lever presses did not result in either cue or drug delivery.
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Figure 2. Experimental Design. (A) Schematic showing viral strategy for excitatory optogenetic
manipulation of pPVT projection neurons within the NAc for patch-clamp electrophysiology.
(B) Illustration of head-fixed setup for saline and heroin self-administration. (C) Timeline
demonstrating experimental procedure for saline and heroin self-administration and heroin
extinction. Adapted from Vollmer & Doncheck et al., 2021.
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Patch-Clamp Electrophysiology
Mice were used for patch-clamp electrophysiology 24 hours following selfadministration. Mice were deeply anesthetized with isoflurane (1.5% in oxygen; 1L/minute) prior
to transcardial perfusion with oxygenated, ice-cold sucrose-based cutting solution containing the
following (in mM): 225 sucrose, 119.0 NaCl, 1.0 NaH2PO4, 4.9 MgCl2, 0.1 CaCl2, 26.2 NaHCO3,
1.25 glucose (305-310 mOsm). After rapid removal, brains were bathed in cutting solution and
coronal sections 300 um thick were taken using a vibratome (Leica VT1200S). Brain slices were
incubated in warm aCSF (32º C) containing the following (in mM): 119 NaCl, 2.5 KCl, 1.0
NaH2PO4, 1.3 MgCl, 2.5 CaCl2, 26.2 NaHCO3, 15 glucose (305-310 mOsm). Slices were allowed
to recover for at least 1 hr and were then visualized using differential interference contrast through
a 40X water-immersion objective mounted on an upright microscope (Olympus BX51) with
constant perfusion of aCSF. Whole-cell patch-clamp recordings were obtained from eYFP+
neurons (PV-INs in PV-Cre mice, D2-MSNs in D2-Cre mice) and eYFP- neurons (putative D1MSNs in D2-Cre mice) located at the virus injection site in anterior/medial NAc shell. Expression
of eYFP was visualized using a blue LED (<1mW) and a GFP epifluorescence filler set.
Borosilicate pipettes (~3.5MΩ) were backfilled with a potassium gluconate-based internal
solution composed of the following (in mM): 130 K-gluconate, 10 KCl, 10 HEPES, 10 EGTA, 2
MgCl2, 2 ATP, 0.2 GTP (pH 7.35, mOsm 280) and used for whole-cell patch-clamp recordings
to characterize action potential waveforms and to measure the amplitude of PVT-NAc synaptic
currents. In a subset of neurons, depolarizing current pulses (800ms; 50pA steps) were applied in
current-clamp mode to verify fluorescence-identified cell types. In doing so, D1- and D2-MSNs
could be confirmed by their relatively limited spike frequency, ramping depolarization, and late
spiking features, while PV-INs could be confirmed based on their fast-spiking properties (Castro
& Bruchas, 2019; Ferguson & Gao, 2018; Gittis et al., 2011; Hu et al., 2014; Klausberger et al.,
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2005; Nuhar et al., 2021; Ruden et al., 2020; Yamada et al., 2016). Neurons of each type were
held at -70mV in voltage-clamp mode and presynaptic ChrimsonR-tdT+ axons from the PVT
were activated using a green LED (10ms pulse, 1mW) pulsed every 10-15 s. To evaluate
functional synaptic innervation from the PVT to each of the NAc cell types, the peak amplitude
of optically evoked excitatory postsynaptic currents (oeEPSCs) was measured and compared
across cell types using a one-way ANOVA followed by Sidak’s post-hoc tests for between group
comparisons. To confirm that oeEPSCs collected were AMPA-mediated, a 10 min bath
application of the glutamatergic AMPA receptor antagonist DNQX (10µM) was performed in a
subset of neurons. A 25 min bath application of the CP-AMPAr antagonist IEM-1640 (50µM;
Gittis et al., 2011) was performed to evaluate expression of CP-AMPArs on the cell membranes
of each cell type. The average amplitude of the AMPA receptor-mediated oeEPSCs was taken
from the first 5 mins of recordings (prior to drug application) and the last 5 mins of recordings
(after drug application), and responses were compared across time and cell types using a twoway ANOVA, followed by Sidak’s post-hoc tests for between group comparisons. Lastly, the
influence of the µ-OR antagonist DAMGO (3uM; Chen et al., 2015) on PV-INs was evaluated
through a 25 min bath application. The average amplitude of the oeEPSCs were taken from the
first 5 mins of recordings (prior to drug application) and the last 5 mins of recordings (after drug
application), and responses were compared across time and cell types using a two-way ANOVA,
followed by Sidak’s post-hoc tests for between group comparisons.
Next, a cesium methylsulfonate-based internal solution composed of the following (in
mM): 117 Cs methanesulfonic acid, 20 HEPES, 2.8 NaCl, 5 TEA, 2 ATP, 0.2 GTP (pH 7.35,
mOsm 280) and perfusion of aCSF combined with a GABA receptor antagonist picrotoxin
(100uM; Zhu et al., 2016) was used to measure the AMPAr-NMDAr ratio and AMPA
rectification. Visually identified neurons were held at -80mV to record optogenetically evoked
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AMPAR-mediated EPSCs, and then held at +50mV to record fast AMPAr- and slow NMDArmediated oeEPSCs. Using this, the AMPAr-NMDAr ratio is calculated by dividing the amplitude
of the AMPAr current (peak current, at -80mV) by the amplitude of the NMDAr current (current
at 50 ms following start of pulse, at +50 mV). AMPAr-NMDAr ratio was compared across
neurons using a one-way ANOVA, followed by Sidak’s post-hoc tests for between group
comparisons. Lastly, a bath application of the NMDA receptor antagonist APV (50µM; Zhu et
al., 2016) was performed to measure AMPA rectification. AMPAr-mediated oeEPSCs were
collected at a range of voltages (-80, -70, -50, -30, -10, +10, +30, +50 mV). The data were
normalized to the peak oeEPSC at -80 mV, and an AMPA rectification index was calculated for
each neuron as I+50mV/-I-70mV, where I is the peak oeEPSC amplitude at each voltage. AMPA
rectification was compared across neurons using a one-way ANOVA, followed by Sidak’s posthoc tests for between group comparisons.
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Chapter 4: Findings
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Overview
The experimental design described above allowed insight into characterizing the PVT
innervation of downstream cellular targets within the NAc that potentially contribute to the
suppression of reward seeking. I tested my hypothesis that PVT innervates these subclasses of
NAc neurons, and does so through different mechanisms, as well as the hypothesis that synaptic
contact between PVT and PV-INs within the NAc is inhibited by opioid use, through a variety of
drug applications and recording techniques. In doing so, I was able to evaluate the characteristics
of these cell-types, break down the circuitry of this pathway, and investigate plasticity that occurs
following heroin use.

Results
Characterization of PVT-NAc Neuronal Innervation
Neurons were fluorescence-identified (Figure 3A, left) and confirmed using depolarizing
current pulses to verify cell type specific firing patterns (Figure 2A, right). By doing so, D1- and
D2-MSNs were confirmed by their limited spike frequency, ramping depolarization, and late
spiking features, while PV-INs were confirmed based on their fast-spiking properties. Patchclamp electrophysiological recordings revealed functional PVT innervation of PV-INs, D1- and
D2-MSNs in the NAc, depicted through example waveforms collected from each cell type (Figure
3B, left). The frequency of neuronal response is shown with pie charts (Figure 3B, right). The
average peak oeEPSC amplitude of PV-INs (Figure 3C: AVG=226.49 pA; SEM=27.13 pA; n=25
cells/9 mice) was significantly greater than that of both D1- (Figure 3C: AVG=51.99 pA;
SEM=9.32 pA; n=20 cells/9 mice) and D2-MSNs (Figure 3C: AVG=68.69 pA; SEM=10.38 pA;
n=28 cells/11 mice) in drug-naive animals (Figure 3C: F2,69=27.78, P<0.001; post-hoc: D1 vs.
PV ****P<0.001, D2 vs. PV ****P<0.001).
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Figure 3. Patch-clamp electrophysiological confirmation of individual cell-types within the
NAc. (A) Example fluorescent images (left) and traces of action potentials (right). (B) Example
waveforms of each cell-type (left) and pie charts representing % of responding neurons (right).
(C) oeEPSC amplitudes of each cell-type revealing elevated NAc PV-IN amplitude (n=20-28
cells; 8-11 mice/group; F2,69=27.78, P<0.001).
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By measuring AMPA receptor oeEPSCs at increasing holding potentials between -80mV
and +50mV, the rectification of AMPA currents were calculated. Example waveform traces
reveal the impact of voltage block at depolarized voltages collected from PV-INs compared to
D1- and D2-MSNs (Figure 4A). AMPA rectification measurements show that PV-INs are
inwardly rectifying (Figure 4B), with a significantly lower rectification index (Figure 4B, inset:
AVG=0.32; SEM=0.05; n=16 cells/7 mice) compared to both D1-MSN (Figure 4B, inset:
AVG=0.75; SEM=0.09; n=12 cells/6 mice) and D2-MSN (Figure 4B, inset: AVG=0.93;
SEM=0.14; n=10 cells/5 mice) rectification indexes (F2,34=13.27, P<0.001; post-hoc: D1 vs. PV
**P=0.003, D2 vs. PV ****P<0.001). With PV-INs displaying inward rectification, suggesting
a higher presence of CP-AMPArs, I bath applied a selective CP-AMPAr antagonist, IEM-1460,
to confirm the presence of and characterize these receptors. Example waveform traces from each
cell-type comparing pre- (5 min baseline) and post-wash (20-25 min) measures visibly show the
difference in effects (Figure 4C). Grouped data from each cell-type reveal that PV-INs responded
to the CP-AMPAr antagonist IEM wash with a significant decrease in peak oeEPSC amplitude
(Figure 4D: pre: AVG=344.54 pA; SEM=43.7 pA; post: AVG=192.14 pA; SEM=32.47 pA; n=10
cells/5 mice). Both D1-MSNs (Figure 4D: pre: AVG=57.25 pA; SEM=18.17 pA; post:
AVG=58.42 pA; SEM=22.45 pA; n=7 cells/5 mice) and D2-MSNs (Figure 4D: pre: AVG=54.47
pA; SEM=13.32 pA; post: AVG=41.23 pA; SEM=12.51 pA; n=6 cells/4 mice) were less
responsive, showing insignificant changes in peak oeEPSC amplitudes following IEM wash (time
x cell: F2,19=13.17, P=0.003; post-hoc: PV ****P<0.001). Additionally, bath application of the
µ-OR agonist DAMGO revealed a decreased response upon PVT activation in example traces
(Figure 4E), and a significant decrease in PV-IN oeEPSC amplitude (Figure 4F: pre:
AVG=399.30 pA; SEM=98.72 pA; post: AVG=164.25 pA; SEM=43.48 pA; n=8 cells/5 mice;
t7=4.12, **P=0.004).
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Figure 4. Patch-clamp electrophysiology data characterizing cell-type specificity and
activity within the NAc. (A) Example waveforms of AMPAr expression at specified voltages.
(B) Grouped data depicting AMPAr rectification, showing that NAc PV-INs are selectively
inwardly rectifying (n=10-16 cells; 5-7 mice/group). Inset: rectification index (I50/-I-70;
F2,34=13.27, P<0.001). (C) Example waveforms and (D) grouped data of pre- and postapplication of CP-AMPAr antagonist IEM-1460, showing selective reduced oeEPSC amplitudes
in NAc PV-INs (n=5-10 cells, 4-5 mice/group; interaction: F2,19=13.17, P=0.003). (E) Example
waveforms and (F) average oeEPSC amplitude of pre- and post-application of µ-OR agonist
DAMGO, showing reduction of PVT amplitude to PV-INs.
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Effects of Chronic Opioid Use on PVT-NAc Neurons
Following heroin self-administration, D1-MSNs did not show a significant change in
average peak oeEPSC amplitude (Figure 5A: AVG=79.46 pA; SEM=19.84 pA; n=22 cells/9
mice) or extinction learning (Figure 5A: AVG=63.56 pA; SEM=11.19 pA; n=18 cells/8 mice;
interaction: F2,58=1.044, P>0.1); however, D2-MSNs showed a significant increase in average
peak oeEPSC amplitude following heroin self-administration (Figure 5B: AVG=131.98 pA;
SEM=16.69 pA; n=19 cells/9 mice) but not following extinction learning (Figure 5B:
AVG=87.19 pA; SEM=14.33 pA; n=21 cells/8 mice; interaction: F2,65=5.693, P=0.005). PV-INs
exhibited a significant decrease in average peak oeEPSC amplitude following heroin selfadministration (Figure 5C: AVG=104.57 pA; SEM=22.63 pA; n=22 cells/7 mice) compared to
control, with a sustained decrease following extinction learning (Figure 5C: AVG=122.40 pA;
SEM=19.97 pA; n=22 cells/5 mice; interaction: F2,66=7.923, P<0.001).
The changes in AMPA-mediated activity were further investigated through AMPArNMDAr ratios, with D1-MSNs presenting no significant changes between control (Figure 5D:
AVG=1.51; SEM=0.61; n=12 cells/6 mice) and heroin self-administration (Figure 5D:
AVG=1.74; SEM=0.46; n=12 cells/5 mice) or extinction learning (Figure 5D: AVG=1.24;
SEM=0.22; n=12 cells/5 mice; interaction: F2,33=0.2986, P>0.1). Similarly, D2-MSNs showed a
small yet insignificant increase in AMPAr/NMDAr ratio between control (Figure 5E: AVG=1.84;
SEM=0.52; n=11 cells/5 mice) and heroin self-administration (Figure 5E: AVG=3.01;
SEM=0.45; n=11 cells/5 mice), with no changes following extinction learning (Figure 5E:
AVG=2.24; SEM=0.73; n=12 cells/5 mice; interaction: F2,31=1.057, P>0.1). In contrast, PV-INs
AMPAr/NMDAr ratio significantly decreased between control (Figure 5F: AVG=5.09;
SEM=0.81; n=18 cells/8 mice) and heroin self-administration (Figure 5F: AVG=3.17;
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SEM=0.55; n=12 cells/6 mice) and extinction learning (Figure 5F: AVG=2.61; SEM=0.45; n=19
cells/5 mice; interaction: F2,37=4.726, P=0.015).
To identify changes in CP-AMPAr expression following heroin use and extinction
learning, AMPA rectification measures were collected from each group and cell-type. Following
heroin self-administration, D1-MSNs showed no significant change in rectification index (Figure
5G: AVG=0.65; SEM=0.07; n=12 cells/5 mice), though following extinction learning, they
displayed inward rectification and exhibited a significant decrease in rectification index (Figure
5G: AVG=0.48; SEM=0.08; n=12 cells/5 mice; interaction: F2,33=2.982, P>0.05). In D2-MSNs,
AMPA rectification did not significantly change following either heroin self-administration
(Figure 5H: AVG=0.64; SEM=0.12; n=11 cells/5 mice) or extinction learning (Figure 5H:
AVG=0.58; SEM=0.12; n=12 cells/5 mice; interaction: F2,30=2.118, P>0.1). Lastly, PV-INs
exhibit less inward rectification compared to control, but do not show significant changes in
AMPA rectification index following heroin self-administration (Figure 5I: AVG=0.55;
SEM=0.12; n=13 cells/5 mice), or extinction learning (Figure 5I: AVG=0.48; SEM=0.1; n=19
cells/5 mice; interaction: F2,45=1.635, P>0.1).
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Figure 5. Patch-clamp electrophysiological data revealing synaptic-plasticity following
chronic heroin use. A-C, Example waveforms depicting cell-type activity in control, heroin, and
heroin ext. mice (left) and average peak amplitudes between groups (right) for (A) D1 (n=18-22
cells, 8-9 mice/group; interaction: F2,58=1.044, P>0.1), (B) D2 (n=19-28 cells, 8-11 mice/group;
interaction: F2,65=5.693, P=0.005), and (C) PV (n=22-25 cells, 5-9 mice/group; interaction:
F2,66=7.923, P<0.001) neurons. D-F, Example waveforms (left) and grouped data (right)
representing AMPAr/NMDAr ratio of (D) D1 (n=12 cells, 5-6 mice/group; interaction:
F2,33=0.2986, P>0.1), (E) D2 (n=11-12 cells, 5 mice/group; interaction: F2,31=1.057, P>0.1), and
(F) PV (n=12-19 cells, 5-8 mice/group; interaction: F2,37=4.726, P=0.015) neurons between
groups. G-I, Example waveforms (left) and grouped data (right) representing AMPAr
rectification of (G) D1 (n=12 cells, 5-6 mice; interaction: F2,33=2.982, P>0.05), (H) D2 (n=1012 cells, 5 mice; interaction: F2,30=2.118, P>0.1), and (I) PV (n=13-19 cells, 5-7 mice/group;
interaction: F2,45=1.635, P>0.1) neurons between groups.
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Discussion
Characterization of PVT-NAc Neuronal Innervation
While published research highlights PVT-NAc involvement in the management of reward
seeking, it highlights a gap in the understanding of how downstream NAc cell populations
contribute to PVT-NAc dependent behaviors including drug seeking. To fill this gap, further
investigation is needed of neurons based on gene expression to isolate unique cell populations
(Iglesias & Flagel, 2021; Kirouac, 2015; McGinty & Otis, 2020). Utilizing transgenic mice, creinducible viruses, and patch-clamp electrophysiology, I was able to isolate and characterize cell
populations which express unique genes. Identification of candidate downstream PVT targets
were based on prior research showing that PVT projections to the NAc form functional synapses
with D1-MSNs, D2-MSNs, and PV-INs (Giannotti et al., 2021; Keyes et al., 2020; Scofield et
al., 2016; Yu et al., 2017). The functional connectivity between PVT and PV-INs within the NAc,
as well as their subsequent contribution to the suppression of reward-seeking, is not well
understood. Using PV-cre and D2-cre transgenic mouse lines, in combination with viral
expression of channelrhodopsin in pPVT projection neurons to the NAc and cre-inducible
fluorescent labeling of specific NAc cell populations, I was able to successfully isolate specific
cell-types in the NAc which receive PVT synaptic signaling. The identities of these cell-types
were confirmed using depolarizing current pulses, as PV-INs are fast-spiking interneurons which
exhibit a high-frequency train of action potentials following current pulses (Castro & Bruchas,
2019; Ferguson & Gao, 2018; Gittis et al., 2011; Hu et al., 2014; Klausberger et al., 2005; Nuhar
et al., 2021; Ruden et al., 2020; Yamada et al., 2016). By contrast, D1- and D2-MSNs exhibit
limited spike frequency, ramping depolarization, and late spiking frequencies (Castro & Bruchas,
2019; Gittis et al., 2011).
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To evaluate functional synaptic innervation from the PVT to each of the NAc cell types,
the peak amplitude of optically evoked excitatory postsynaptic currents (oeEPSCs) was
measured. Neurons of each type responded to activation of the excitatory opsin, revealing
functional PVT innervation of PV-INs, D1- and D2-MSNs (Figure 6A). Peak amplitudes
collected from PV-INs in control mice were significantly greater than those collected from both
D1- and D2-MSNs, suggesting PV-INs receive elevated glutamatergic excitatory synaptic drive
compared to MSNs (Figure 6B). The excitatory synapses on NAc PV-INs have been shown to be
highly enriched in CP-AMPArs (Gittis et al., 2011; Lalanne et al., 2018; Nuhar et al., 2021; Ruden
et al., 2020), which likely contribute to the increased strength of PVT innervation, indicating that
PV-INs express a greater amount of AMPArs overall compared to D1- and D2-MSNs (Figure
6D-E). We performed a control experiment using the glutamatergic AMPAr antagonist DNQX
to confirm the source of the responses collected. Importantly, oeEPSCs collected were confirmed
to be AMPA-mediated, as bath application of DNQX abolished responses in the subset of neurons
it was performed.
When evaluating expression of glutamatergic receptors, AMPA-NMDA ratio can be
helpful to analyze and compare between cell-types and groups, providing the relative expression
of AMPA and NMDA receptors at the synapse. The average AMPAr-NMDAr ratio was
significantly higher in PV-INs compared to both D1- and D2-MSNs. These data further support
the idea that PV-INs express a higher amount of AMPArs than MSNs. Both MSNs had similar
AMPAr-NMDAr ratios, with D2-MSNs showing a slightly higher amount of AMPAr expression.
To analyze the characteristics of these AMPArs, I looked at AMPA rectification which is
useful in identifying the types of AMPArs that are being expressed on the cell membrane.
AMPARs that lack the GluA2 subunit are calcium-permeable and exhibit a voltage dependent
channel block, which greatly limits current flow at depolarized voltages (Carlezon & Thomas,
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2009; Goffer et al., 2013; Lalanne et al., 2018). I observed that PV-INs are inwardly rectifying,
represented by having decreased oeEPSC amplitudes at depolarized voltages, which is indicative
of CP-AMPAr expression. In contrast, D1- and D2-MSNs are not inwardly rectifying, both
having a significantly higher rectification index compared to PV-INs, implying that these MSNs
do not express the high amount of CP-AMPArs that are seen within PV-INs. Between the two
MSNs, D1- and D2-MSNs show similar AMPA rectification results, with D2-MSNs having a
slightly higher rectification index compared to D1-MSNs. The difference seen between D1- and
D2-MSNs is insignificant, although differences between these cell types are common as they
often contribute to opposing physiological and drug-associated behavioral effects (Carlezon &
Thomas, 2009; Yager et al., 2015; Zhu et al., 2016).
To confirm the presence of CP-AMPArs, I then assessed the sensitivity of each cell-type
to IEM-1460. Use of the selective CP-AMPAr antagonist IEM-1460 further assists in identifying
the types of AMPArs that are contributing to the responses seen (Gittis et al., 2011; Samoilova et
al., 1999; Schlesinger et al., 2005). Following a 25 min bath application of IEM-1460, average
peak oeEPSC amplitudes collected from PV-INs significantly decreased to almost half of their
original amplitude, establishing the presence of CP-AMPArs on their membrane. As expected,
D1- and D2-MSNs were less responsive to IEM-1460, showing slight yet non-significant changes
in peak oeEPSC amplitudes following wash-on. These data confirm our hypothesis that PVT
neuronal innervation of PV-INs within the NAc is through CP-AMPArs, and previous literature
has shown that PV-INs extensively innervate MSNs within the NAc, which are critical for
reward-seeking behavior (Figure 6C) (Castro & Bruchas, 2019; Gittis et al., 2011; Nuhar et al.,
2021; Owen et al., 2018). These findings lead to identification of a feedforward inhibitory circuit,
in which the GABAergic effects of PV-INs inhibit MSNs, a critical mechanism for the
suppression of reward-seeking.
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Lastly, as part of another ongoing project, our lab has recently investigated and confirmed
co-expression of µ-ORs with virally labeled PVT-NAc neurons (Vollmer & Green et al.,
submitted). As GPCRs, µ-ORs are a molecular target for many opioid drugs, and while these
receptors are thought to also be involved in OUD, there is still much to learn about their
mechanisms and contribution (Castro & Bruchas, 2019; Cuitavi et al., 2021; Merrer et al., 2009;
Ugar et al., 2018). Using this knowledge of µ-OR expression, I investigated the influence of these
receptors within the PVT-NAc pathway. The µ-OR agonist DAMGO was used to test for the
presence of these receptors on PV-INs. Following a 25 min bath application, PV-INs showed a
significant decrease in oeEPSC amplitude compared to baseline. This attenuation of synaptic
strength seen in PV-INs could imply that µ-ORs influence the mechanism by which PVT
suppresses reward seeking. While these data are helpful in setting a foundation of knowledge on
the circuitry and mechanism of this pathway, in what manner this process is affected by opioid
use is unclear.
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Figure 6. Visualization of characteristics of PVT innervation of downstream NAc neurons
in drug-naïve mice. A-C, PVT synaptically innervates PV-INs, D1-MSNs, and D2-MSNs (A),
and the PVT synaptic drive is stronger at PV-IN synapses (B), therefore causing PV-IN inhibition
of D1- and D2-MSNs (C). D-E, CP-AMPArs are expressed on PV-INs (D), and in great amounts
detected through AMPA rectification measures (E). (F) D1- and D2-MSNs express µ-ORs within
the NAc.
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Effects of Chronic Opioid Use on PVT-NAc Neurons
Recent data from our lab suggest that activity in thalamostriatal neurons changes as a
function of opioid use, wherein chronic heroin use causes the PVT-NAc pathway to become
dysfunctional such that activation of PVT-NAc neurons provokes reward-seeking rather than
suppresses it (Vollmer & Green et al., in prep). We showed that inhibition of pPVT-NAc
promotes sucrose seeking, even when that seeking would be considered inappropriate, such as
after exposure to both a natural and pharmacological stressor. However, activation of pPVT-NAc
decreases reward seeking and serves as a brake on reward-seeking behaviors. Here, I tested our
hypothesis that the synaptic contact between PVT and PV-INs within the NAc is inhibited by
opioid use. To do so, I evaluated the activity dynamics of single PVT-NAc neurons using credriver mouse lines for targeting unique cell types, excitatory optogenetics, and patch-clamp
electrophysiology in mice following heroin self-administration and extinction.
To measure the synaptic strength of PVT neurons to downstream cell-type specific NAc
neurons, oeEPSC recordings were collected from PV-INs, D1- and D2-MSNs following saline
self-administration, heroin self-administration, and heroin extinction. I observed that PV-INs
showed a significant decrease in average peak oeEPSC amplitude following heroin selfadministration compared to saline-treated mice (Figure 7A). The decreased responses seen here
reveal a decrease in glutamatergic excitatory drive on PV-INs, and importantly, this decrease
remains persistent throughout heroin extinction (Figure 7C). An important characterization of
OUD includes relapse, where individuals often resort to using opioids again after obtaining
abstinence. It is known that after opioid use, the brain undergoes gradual changes which
reorganizes the circuitry, leading to the effects of OUD and relapse. The investigation of longterm neuroadaptive changes in the brain following opioid use can help discover why individuals
who suffer from OUD often face long-term impaired inhibitory control and impulsivity which
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contributes to relapse (Kalivas & Volkow, 2005; Matzeu & Martin-Fardon, 2018; Zhou & Zhu,
2019). The lasting changes seen in PV-INs following heroin self-administration and extinction
could provide valuable insight into the mechanisms of relapse. Recordings from D1-MSNs show
relatively consistent average peak oeEPSC amplitudes following saline self-administration,
heroin self-administration, and heroin extinction, with no significant changes. Interestingly, D2MSNs showed a significant increase in average peak oeEPSC amplitude following heroin selfadministration, but this change did not persist throughout heroin extinction (Figure 7A, C). The
increase in glutamatergic excitatory synaptic drive on D2-MSNs could be accomplished by
synaptic insertion of AMPArs, which would lead to an increase in oeEPSC amplitude, as seen. It
has been proposed that D1- and D2-MSNs play opposing roles in mediating behavioral
motivation and reward learning (Carlezon & Thomas, 2009; Yager et al., 2015; Zhu et al., 2016),
which could explain the contrasting results I collected for these cell types.
Next, I looked at the ratio of AMPAr- and NMDAr-mediated oeEPSCs to detect any
changes in receptor expression. Glutamatergic synaptic transmissions are controlled through the
activity of fast AMPA and slow NMDA receptors. By analyzing strength of these responses, we
are able to detect any changes that could induce long-term depression or long-term potentiation
(Ruden et al., 2020). I saw that the AMPAr-NMDAr ratio in PV-INs significantly decreased
following heroin self-administration and heroin extinction which is due to a maintained decrease
in AMPAr-mediated synaptic activity. Following heroin self-administration, D2-MSNs revealed
a slight increase in AMPAr-NMDAr ratio, while heroin extinction did not change compared to
control. This is expected with the increase seen in D2-MSN synaptic strength, although the
changes were not enough to cause a significant change. The AMPAr-NMDAr ratio of D1-MSNs
following heroin and heroin extinction did not exhibit any significant changes compared to
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control. These data reveal that while there were no consistent changes seen in MSNs, PV-INs
receive a significant decrease in PVT synaptic input.
To evaluate the differences seen thus far, I also collected AMPA rectification
measurements to identify changes in the type of AMPAr being expressed. The oeEPSCs
measured at depolarized voltages following heroin self-administration and heroin extinction were
greater than that for PV-INs seen in control animals, suggesting a decrease in CP-AMPAr
expression. Although the rectification index for PV-INs following both heroin self-administration
and heroin extinction slightly decreased, these results were not statistically significant. The
rectification index for D1-MSNs did not change following heroin self-administration, and
significantly decreased following heroin extinction (Figure 7D). We see a similar effect in D2MSNs, where the rectification index decreases following heroin self-administration and currents
become more inwardly rectifying than seen in control animals. Following heroin extinction, D2MSNs showed a consistent change as heroin self-administration, implying that these changes
were persistent, although they were not statistically significant. A recent study showed that D2MSNs undergo synaptic insertion of CP-AMPArs following morphine exposure (Zhu et al., 2016)
and, while the effects may not be as strong, we see a similar trend following heroin selfadministration.
These data revealed significant changes in the downstream targets of PVT following
heroin self-administration and heroin extinction; however, how these changes contribute to
heroin seeking behavior remains unknown. It is understood that PV-INs make numerous synapses
with other neurons and interneurons, though they preferentially innervate the somata of MSNs
more than any other identified source (Castro & Bruchas, 2019; Gittis et al., 2011; Nuhar et al.,
2021). The decrease in PV-IN activity following heroin self-administration and heroin extinction,
and subsequent loss of inhibitory effects on MSNs, offers a potential explanation for why we see
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an increase in activity within D2-MSNs. However, since D1- and D2-MSNs often have different
physiological characteristics and cause opposing effects in drug-associated behaviors, it is
suggested that these MSNs also present different types of plasticity following heroin use. The
heterogeneity of the PVT-NAc pathway presents additional hurdles when attempting to map and
understand the circuitry that underlies the behavioral effects caused by opioids (McGinty & Otis,
2020). It is necessary to consider that this heterogeneous nature may provide alternative points
of interest in how this pathway functions and how it is affected following opioid use. Overall, the
experiments that were performed here indicate that the feedforward inhibitory circuit consisting
of PV-INs and MSNs within the PVT-NAc pathway plays a large role in the suppression of
reward-seeking behaviors in relation to heroin use and heroin extinction.
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Figure 7. Visualization of synaptic plasticity in downstream NAc neurons following heroin
and heroin extinction. A-B, Following chronic heroin use, PVT synaptic drive increases to D2MSNs, decreases to PV-INs, and remains unchanged to D1-MSNs (A), leading to decreased
inhibition of D1-and D2-MSNs by PV-INs (B). (C) Following heroin extinction learning, PVT
synaptic drive decreases to D2-MSNs and remains consistently low to PV-INs. (D) Expression
of CP-AMPArs increases on D1-MSNs following heroin extinction learning shown by a decrease
in AMPA rectification index.
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Chapter 6: Conclusion
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Conclusion
The PVT-NAc pathway has been shown to play a critical role in reward-seeking behavior,
though the downstream activity dynamics have not been fully evaluated. Previous work
investigates the influence of this pathway on natural and maladaptive reward-seeking, leading to
the understanding that activation of this pathway discourages seeking, but the literature highlights
a gap in knowledge regarding cell-type specific activity in this pathway. Dissection of the precise
synaptic contacts of PVT to downstream NAc neurons is required to have a foundation on which
to build deeper knowledge about how this connection changes in the context of OUD. Here, I
find that PVT innervates PV-INs, D1- and D2-MSNs within the NAc, and that PV-INs express a
higher amount of CP-AMPArs compared to MSNs. Recent data from our lab also suggest that
activity in thalamostriatal neurons changes as a function of opioid use, where heroin use causes
the PVT-NAc pathway to become dysfunctional such that activation of PVT-NAc neurons
provokes reward-seeking rather than suppresses it (Vollmer & Green et al., in prep). By
evaluating peak oeEPSC amplitude, AMPAr-NMDAr ratio, and AMPA rectification, I was able
to measure significant changes in cell-type characteristics, importantly seen within PV-INs and
D2-MSNs, following opioid use. The changes observed in D1- and D2-MSNs support those
shown in a similar study investigating modifications following morphine exposure (Zhu et al.,
2016), and the identification of synaptic plasticity associated with PV-INs and their physiological
and molecular features contribute to an expanded understanding of how these circuits interact in
congruence with one another. Although we determined that these circuits become dysfunctional
following chronic opioid use in a manner that influences alternate activity in multiple cell-types
within the NAc, further dissection of how this circuit affects the behavioral effects caused by
opioid use is necessary to identify possible targets for OUD treatment.
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Future Directions
Identification of thalamostriatal circuitry involved in OUD is critical to understanding the
mechanisms and preventative measures necessary to cause and prevent addiction. Previous
studies have seen that the use of µ-OR agonist DAMGO causes reinstatement of cocaine selfadministration (Simmons & Self, 2009), and here we saw that DAMGO causes a decrease in the
synaptic strength of PV-INs receiving input from the PVT. While these changes indicate the
involvement of µ-ORs in the ability of PVT-NAc pathway to suppress reward-seeking, the
precise mechanism of action as well as behavioral effects of µ-OR plasticity are not yet
understood. Investigating the activity of µ-ORs within this circuit and how their activity
influences behavioral motivation and reward-seeking will be important in future research to fully
elucidate their association in OUD. As we identified the expression of µ-ORs on PV-INs, it could
be useful to perform patch-clamp electrophysiology to test for the expression of µ-ORs on D1and D2 MSNs within the NAc as well and evaluate if their activity changes with the application
of DAMGO. Furthermore, how µ-OR expression and activity influences behavior will also
provide valuable information in determining their involvement in OUD. Using designer receptors
exclusively activated by designer drugs (DREADDs), it could be possible to see how the
activation and inhibition of µ-ORs affects behavior and drug-seeking in awake, behaving mice.
Additionally, while this circuit is implicated in OUD, it has also been shown to be
involved in alcohol abuse and addiction as well (Dayas et al., 2008). As such, I investigated how
this circuit changes following ethanol use compared to heroin use in regard to PV-INs within the
NAc, as part of an ongoing study being performed in collaboration with Dr. Jennifer Rinker.
Using the same viral strategy allowing for the identification of fluorescently labeled neurons and
manipulation of PVT projection neurons within the NAc, mice completed chronic intermittent
ethanol (CIE) or air exposure and underwent patch-clamp electrophysiology experimentation 24
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hrs following their last session. While this experiment is still in progress, we have seen an overall
decrease in PV-IN activity, as well as a significant decrease in AMPA-NMDA ratio and decrease
in AMPA rectification in mice exposed to CIE. With similar results to the changes seen following
heroin use, it is possible that alcohol addiction uses a similar mechanism as OUD. Interestingly,
previous research has linked activation of µ-ORs with an increase in alcohol consumption
(Richards & Fields, 2016), and a prior study found that genetically engineered µ-OR knockout
mice do not self-administer ethanol and exhibited aversive behavior (Roberts et al., 2000). Further
examination of the contribution of cell-type and µ-OR activity to alcohol abuse is needed to
understand how this circuit contributes to alcohol abuse and to evaluate whether µ-OR activity
could be an overlapping mechanism of both opioid and alcohol addiction.
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